ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49165
0.00%
Bitcoin
67,153.03
0.32%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) News

OGN

Organon (OGN)

Organon and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OGN
DateTimeSourceHeadlineSymbolCompany
18/05/202406:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
08/05/202410:20Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
08/05/202406:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/05/202406:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/05/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/05/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/05/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/05/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
08/05/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:58Business WireOrganon Announces Proposed $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
02/05/202421:30Business WireOrganon Reports Results for the First Quarter Ended March 31, 2024NYSE:OGNOrganon and Co
09/04/202422:13Business WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
09/04/202404:31Business WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
09/04/202404:31Business WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
08/04/202420:15Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
08/04/202420:00Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
09/03/202401:01PR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
09/03/202401:01PR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
02/03/202408:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
02/03/202408:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
02/03/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
02/03/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
27/02/202400:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:OGNOrganon and Co
24/02/202403:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
21/02/202400:00Business WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National FormularyNYSE:OGNOrganon and Co
15/02/202423:48Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
15/02/202423:30Business WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023NYSE:OGNOrganon and Co
14/02/202408:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
01/02/202423:30Business WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024NYSE:OGNOrganon and Co
10/01/202423:33Business WireOrganon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and OlderNYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

Your Recent History

TSXV
AGY.H@OL
COIN
DYDXEUR
dYdX
USOTC
GNYPF
Masivo Silver (PK)
LBNK
NUMUSDT
NUM Token
BIT
P20912
NLBNPIT20912 20991231 11...
BIT
XCAN
DB X-Trackers MSCI Canad...
BIT
UB2AZA
UniCredit Bank
KOSPI
610004
Us Leverage Inflation Bo...
DBI
4N93
DAXsubsector All Industr...
BIT
UB1X6G
UniCredit Bank
LSE
0HLU
Baozun
EU
BPCHM
BPCE Bpce3.50%14dec26
EU
I513T
I513T
USOTC
TLCC
Twinlab Consolidated (PK)
COIN
ADSTGBP
NASDAQ
BULKU
Navios Maritime
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved